Trial Profile
Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Oct 2020
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 03 Aug 2018 Planned End Date changed from 1 Mar 2018 to 1 Oct 2018.
- 03 Aug 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2018.
- 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.